Our study “Implementation of an AI-supported decision-making tool in a high-volume stroke system with routine perfusion imaging“ is just out in European Stroke Journal!
970 consecutive EVTs at @sahlgrenska (2021–2024).
Implementation of @Brainomix 360 Stroke - year 2022.
Adjusted CT-to-puncture: from 47 min (pre-implementation) → 35 min (established period)
Largest gains at the primary stroke centres:
• CT-to-puncture −21.2 min
• CT-to-perfusion maps −3.7 min
• working hours: −28 and −6.4 min
At the CSC the effect was smaller (−4.5 min CT-to-puncture in working hours).
In an already optimised network as ours, the time was saved where it is usually hardest: the referring hospitals. Faster maps and occlusion detection likely cut diagnostic uncertainty. EVT numbers also rose in the established period.
Open access: https://t.co/4JzU9b5ioW
Congrats to our first author (and now PhD) Adrian Karlsson, and the whole team.
@Brainomix@NN_publishing@ESOstroke
#Stroke #EVT #Neurointervention
#STROKE: Simultaneous publication at #ESOC2026 🔴🔵: Unsuccessful recanalization occurs in ~30% of all EVT cases, and it remains highly challenging to predict which patients will experience it. EVT should still be offered to all eligible patients. https://t.co/yH9in3OjOI
#ISC26@StrokeAHA_ASA
ORIENTAL-MeVO: A positive trial in MeVO space shows that EVT within 24 hrs of sx onset among pts with moderate/high clinical severity improved 90-day functional outcomes without increasing mortality or sICH @RaulNogueiraMD
📚CHOICE II #ISC26
✅️ IA Alteplase following successful thrombectomy
✅️ Increases the rates of excellent functional outcomes
✅️ Reduces persistent hypoperfusion
✅️ Does not increase the risks of sICH
Our @TheJNS paper is out: In perimesencephalic SAH, high-res CBCT frequently identifies a basilar perforator pseudoaneurysm supporting an arterial etiology until proven otherwise. Conservative management was associated with excellent outcomes. https://t.co/eL5vELrIKA
#ISC26 CHOICE 2 TRIAL - IA alteplase following successful thrombectomy increases the rates of excellent function outcome, reduces the rate of persistent hypoperfusion without increasing risk of ICH.
In an observational cohort study, unwitnessed patients with LVO undergoing EVT had at least the same likelihood of favorable outcomes as witnessed patients when presenting in the extended time window. https://t.co/vsT1TsUEKK
@PrCCordonnier@NguyenThanhMD@NagelSimon@shadiyaghi2
Landmark CREST-2 trial just released at #SVIN25. The trial is positive!! Benefit of CAS+MM over MM alone in asymptomatic high grade carotid stenosis. More importantly, no benefit seen for CEA+MM compared to MM alone.
Exciting times ahead!
Presented at #SVIN25:
CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: https://t.co/ojge1CjqiU
Editorial: Managing Asymptomatic Carotid Stenosis https://t.co/D9LH89Edyk
@svinsociety
#Stroke InterSECT by @DotunOlalusi et al.: To tackle strokophobia, stroke education should be tailored to improve confidence and clinical outcome. https://t.co/WaipdkJpC8
In a systematic review and study-level meta-analysis, TNK improved excellent functional outcomes and recanalization in AIS patients treated within 4.5-24 hours, without increasing the risks of sICH or mortality. #stroke https://t.co/6m34Pm2pyJ
🧵/ Late breaking science results from #ISC25 will be posted to this thread at the time of presentation.
(bookmark this post)
DISTAL
ESCAPE-MeVO
DISCOUNT
TRANSPORT2
C3FIT
PRESTIGE-AF
ANGEL-TNK
HOPE
Patients with evidence of microplastics and nanoplastics in carotid artery plaque, as compared with patients without, had a greater risk of adverse cardiovascular events at 34 months of follow-up. Read the full article: https://t.co/BUsdzHMcdb
EMBOLISE Trial: Surgical Cohort results announced at #ISC24
MMA embolization with Onyx led to a 3-fold reduction in recurrences requiring surgical drainage compared to
Surgery Alone - per CEC adjudication (4.1% vs 11.3%, p=0.0081).
NNT14!
#ISC24